Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

about

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

Item

http://www.wikidata.org/entity/Q48234943

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@en

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@nl

type

Item

label

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@en

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@nl

prefLabel

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@en

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor.

@nl

P1476

Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor

@en

P2093

Emi Ushigome

http://www.w3.org/2001/XMLSchema#string

Hiroshi Okada

http://www.w3.org/2001/XMLSchema#string

Koji Nakano

http://www.w3.org/2001/XMLSchema#string

Masahiro Yamazaki

http://www.w3.org/2001/XMLSchema#string

Muhei Tanaka

http://www.w3.org/2001/XMLSchema#string

Naoto Nakamura

http://www.w3.org/2001/XMLSchema#string

Yohei Oda

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Association between coffee consumption and the estimated glomerular filtration rate in the general Japanese population: preliminary data regarding C-reactive protein concentrations.

Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis.

Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

Effects of caffeine on human health.

Urine volume and change in estimated GFR in a community-based cohort study.

Coffee consumption and risk of type 2 diabetes: a systematic review.

P304

694-699

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DMRR.2789

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yoshitaka Hashimoto

Michiaki Fukui

P577

2016-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295076673

http://www.w3.org/2001/XMLSchema#string

P698

26891133

http://www.w3.org/2001/XMLSchema#string